Page last updated: 2024-11-09

ace-011

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ACE-011: a dimeric fusion protein consisting of the extracellular domain of the human ActRIIA linked to the Fc portion of human IgG1 and may be an effective therapy in a variety of diseases involving bone loss [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2877953
SCHEMBL ID2204761
MeSH IDM0537365

Synonyms (24)

Synonym
CBMICRO_030367
ace-011
OPREA1_342150
DIVK1C_005743
CDS1_004703 ,
BIM-0030123.P001
n-(2-ethoxy-4-nitrophenyl)acetamide
AKOS001044796
116496-76-5
4-acetamido-3-ethoxynitrobenzene
acetamide, n-(2-ethoxy-4-nitrophenyl)-
PS-6223
AB07920
acetamide,n-(2-ethoxy-4-nitrophenyl)-
n-(2-ethoxy-4-nitrophenyl) acetamide
XZWVZJDHIDYKPB-UHFFFAOYSA-N
mfcd00994990
SCHEMBL2204761
DTXSID60387001
SR-01000223946-1
sr-01000223946
FT-0715219
4-(4-ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic acid tert-butyl ester
Z56871699

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Sotatercept was generally safe and well tolerated, and elicited clinically significant, dose-dependent increases in hemoglobin, hematocrit, and red blood cell counts that persisted for up to 4 months."( Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
Borgstein, NG; Chen, N; Kim, K; Kumar, R; Laadem, A; Mook, L; Sherman, ML; Wilson, D; Yang, Y, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we evaluated the safety, pharmacokinetic properties, and pharmacodynamic effects of sotatercept in 31 healthy postmenopausal women."( Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
Borgstein, NG; Chen, N; Kim, K; Kumar, R; Laadem, A; Mook, L; Sherman, ML; Wilson, D; Yang, Y, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" The absorption after subcutaneous dosing was essentially complete."( Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.
Condon, CH; Jacobs, M; Kramer, W; Kumar, R; Pearsall, AE; Ruckle, J; Seehra, J; Sherman, ML; Underwood, KW; Yang, Y, 2009
)
0.59
" A particular emphasis is given to the relationship between sotatercept dosage and its efficacy or associated adverse reactions."( From bench to bedside: The promise of sotatercept in hematologic disorders.
Lan, Z; Lv, Z; Xiao, Y; Zuo, W, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.17)29.6817
2010's29 (63.04)24.3611
2020's16 (34.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.98 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index5.70 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (21.28%)5.53%
Reviews10 (21.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (57.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]